The Department of Medicine is thrilled to announce that Huda Salman, M.D, Ph.D., was awarded a clinical trial research grant from the U.S. Food and Drug Administration, one of only six FDA grants whose focus is to enhance the development of medical products for patients with rare diseases. Dr. Salman’s R01 FDA/NIH R01 grant is titled “CD4 Redirected Chimeric Antigen Receptor T Cell Therapy for CD4 Positive T Cell Neoplasms.” The grant totals $3.1 million over four years.
The U.S. Food & Drug Administration stressed the importance of clinical trials in its October 8, 2020 press release:
“Now, more than ever, we see the important role of these FDA grants to support clinical trials of potentially life-changing treatments for patients with rare diseases,” said FDA Commissioner Stephen M. Hahn, M.D. “As interest in the program has grown, so has the hope for promising approved therapies for patients with rare diseases that currently have no treatment options. These important clinical trials are at a critical time where additional resources are needed to support rare disease research during the COVID-19 pandemic.”
“The grants awarded support clinical studies of products that address unmet needs in rare diseases or conditions, or provide highly significant improvements in treatment or diagnosis.”
Dr. Salman, part of the Stony Brook medical hematology/oncology team, is an Associate Professor of Medicine, Section Chief, Hematological Malignancies, and Director, CAR T Cell Program at Stony Brook University and the Stony Brook Cancer Center. The Hematologic Malignancies and Stem Cell Transplant team treats blood-related cancers and cancers of the lymphatic system.
Congratulations to Dr. Salman on being awarded this critically important and very competitive grant, and we wish her continued success in her research endeavors.
